Skip to content
2000
Volume 17, Issue 9
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto- treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these agents in the management of MPM.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520617666170102151918
2017-08-01
2025-04-09
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520617666170102151918
Loading

  • Article Type:
    Research Article
Keyword(s): immune; ipilimumab; Mesothelioma; pembrolizumab; prognostic value; tremelimumab
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test